Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.

Authors

Raphael J Landovitz
Sue Li
Joseph J Eron
Beatriz Grinsztejn
Halima Dawood
Albert Y Liu
Manya Magnus, George Washington University
Mina C Hosseinipour
Ravindre Panchia
Leslie Cottle
Gordon Chau
Paul Richardson
Mark A Marzinke
Susan H Eshleman
Ryan Kofron
Adeola Adeyeye
David Burns
Alex R Rinehart
David Margolis
Myron S Cohen
Marybeth McCauley
Craig W Hendrix

Document Type

Journal Article

Publication Date

6-1-2020

Journal

Lancet HIV

DOI

10.1016/S2352-3018(20)30106-5

Comments

Online ahead of print

APA Citation

Landovitz, R., Li, S., Eron, J., Grinsztejn, B., Dawood, H., Liu, A., Magnus, M., Hosseinipour, M., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M., Eshleman, S., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A., Margolis, D., Cohen, M., McCauley, M., & Hendrix, C. (2020). Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.. Lancet HIV, (). http://dx.doi.org/10.1016/S2352-3018(20)30106-5

Peer Reviewed

1